文献速递血液净化与透析水电解质与酸碱

甲状旁腺切除术与口服西那卡塞对腹膜透析晚期继发性甲状旁腺功能亢进患者心血管参数的影响(PROCEED):一项随机试验

Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本先导性前瞻性随机试验在两家大学附属医院纳入65例成人腹膜透析晚期继发性甲状旁腺功能亢进患者,随机接受口服西那卡塞或甲状旁腺全切加前臂自体移植。12个月内两组左心室质量指数、冠状动脉钙化评分、心脏瓣膜钙化评分、主动脉脉搏波速度及健康相关生活质量变化均无差异,但两组血钙、磷、全段甲状旁腺激素均显著下降。西那卡塞组高钙血症相关住院比例低于手术组(1.8% vs 16.7%,P = .005)。

要点

  • 两组左心室质量指数、冠状动脉钙化、瓣膜钙化、主动脉僵硬度和生活质量变化均无差异。
  • 西那卡塞组高钙血症相关住院比例为1.8%,低于甲状旁腺切除术组的16.7%(P = .005)。
  • 作者认为西那卡塞可替代甲状旁腺切除术治疗晚期继发性甲状旁腺功能亢进。

核心结论

  • 西那卡塞与甲状旁腺切除术均有效改善慢性肾脏病-矿物质骨病多项生化异常,但仅稳定而未降低左心室质量、冠状动脉及心脏瓣膜钙化或动脉僵硬,也未改善以患者为中心的健康相关生活质量。
  • 作者认为西那卡塞可替代甲状旁腺切除术用于治疗晚期继发性甲状旁腺功能亢进。
  • 需要长期且把握度充分的研究评估甲状旁腺切除术与西那卡塞对透析患者硬性心血管结局的影响。

研究设计与样本

  • 先导性前瞻性随机试验,在两家大学附属医院开展,纳入65例成人腹膜透析晚期继发性甲状旁腺功能亢进患者,随机接受口服西那卡塞或甲状旁腺全切加前臂自体移植。
  • 主要终点为12个月内通过心脏磁共振成像测量的左心室质量指数变化和冠状动脉钙化评分变化。
  • 次要终点包括12个月内心脏瓣膜钙化评分、主动脉僵硬度、慢性肾脏病-矿物质骨病生化参数及健康相关生活质量指标的变化。
  • 试验注册号:ClinicalTrials.gov NCT01447368。

主要发现

  • 两组左心室质量指数、冠状动脉钙化评分、心脏瓣膜钙化评分、主动脉脉搏波速度和健康相关生活质量变化组间及组内均无差异。
  • 两组血浆钙、磷和全段甲状旁腺激素均显著下降。
  • 西那卡塞组心血管相关住院多于甲状旁腺切除术组(P = .008),校正基线心力衰竭差异后差异不显著(P = .43)。
  • 相同监测频率下,西那卡塞组因高钙血症住院比例为1.8%,低于甲状旁腺切除术组的16.7%(P = .005)。
  • 两组健康相关生活质量指标均无显著变化。

临床怎么用

  • 作者认为西那卡塞可替代甲状旁腺切除术用于治疗晚期继发性甲状旁腺功能亢进。
  • 需要长期且把握度充分的研究评估甲状旁腺切除术与西那卡塞对透析患者硬性心血管结局的影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This trial aimed to evaluate oral cinacalcet versus total parathyroidectomy (PTx) with forearm autografting on cardiovascular surrogate outcomes and health-related quality of life (HRQOL) measures in dialysis patients with advanced secondary hyperparathyroidism (SHPT). DESIGN: In this pilot prospective randomized trial conducted in two university-affiliated hospitals, 65 adult peritoneal dialysis patients with advanced SHPT were randomized to receive either oral cinacalcet or PTx. Primary endpoints were changes in left ventricular (LV) mass index by cardiac magnetic resonance imaging and coronary artery calcium scores (CACS) over 12 months. Secondary endpoints included changes in heart valves calcium scores, aortic stiffness, biochemical parameters of chronic kidney disease-mineral bone disease (CKD-MBD) and HRQOL measures over 12 months. RESULTS: Changes in LV mass index, CACS, heart valves calcium score, aortic pulse wave velocity and HRQOL did not differ between groups or within groups, despite significant reductions in plasma calcium, phosphorus and intact parathyroid hormone in both groups. Cinacalcet-treated patients experienced more cardiovascular-related hospitalizations than those who underwent PTx (P = .008) but the difference became insignificant after adjusting for baseline difference in heart failure (P = .43). With the same monitoring frequency, cinacalcet-treated patients had fewer hospitalizations due to hypercalcemia (1.8%) than patients who underwent PTx (16.7%) (P = .005). No significant changes were observed in HRQOL measures in either group. CONCLUSIONS: Both cinacalcet and PTx effectively improved various biochemical abnormalities of CKD-MBD and stabilized but did not reduce LV mass, coronary artery and heart valves calcification, or arterial stiffness, or improve patient-centered HRQOL measures in PD patients with advanced SHPT. Cinacalcet may be used in place of PTx for treating advanced SHPT. Long-term and powered studies are required to evaluate PTx versus cinacalcet on hard cardiovascular outcomes in dialysis patients. Trial registration: ClinicalTrials.gov identifier: NCT01447368.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Wang AY, Lo WK, Cheung SC, et al. Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial. Nephrol Dial Transplant. 2023. PMID: 36869794. doi:10.1093/ndt/gfad043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。